The document this correction applies to
Timely disclosureWhat was corrected and how
A subsequent correction by the company to the contents of an already published filing.
“Notice concerning the acquisition of an equity interest in Haupt Pharma Wülfling GmbH by a consolidated subsidiary of the Company (making it a sub-subsidiary)” and “Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)”
Open the original documentThe 【Title】, 【opening of the main text (preamble)】 and 【3. Overview of the sub-subsidiary to be transferred (HPW), (1) Name】 of the “Notice concerning the acquisition of an equity interest in Haupt Pharma Wülfling GmbH by a consolidated subsidiary of the Company (making it a sub-subsidiary),” and 【page 11 of the attached materials】 (notes on significant subsequent events) of the “Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)”
Haupt Pharma Wülfling GmbH
Haupt Pharma Wülfing GmbH
There are no corrections to the numerical data.
Because the alphabetic spelling of the corporate name of the company subject to the equity interest acquisition was incorrect.
| Item | Details |
|---|---|
| Disclosure subject to correction | “Notice concerning the acquisition of an equity interest in Haupt Pharma Wülfling GmbH by a consolidated subsidiary of the Company (making it a sub-subsidiary)” and “Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)” |
| Original disclosure date | 26 October 2026, 4 November 2026 |
| Location of correction | The 【Title】, 【opening of the main text (preamble)】 and 【3. Overview of the sub-subsidiary to be transferred (HPW), (1) Name】 of the “Notice concerning the acquisition of an equity interest in Haupt Pharma Wülfling GmbH by a consolidated subsidiary of the Company (making it a sub-subsidiary),” and 【page 11 of the attached materials】 (notes on significant subsequent events) of the “Summary of Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)” |
| Details of correction | Haupt Pharma Wülfling GmbH → Haupt Pharma Wülfing GmbH |
| Reason for correction | Because the alphabetic spelling of the corporate name of the company subject to the equity interest acquisition was incorrect. |
| Impact on Business Performance | There are no corrections to the numerical data. |
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because the alphabetic spelling of the corporate name of the company subject to the equity interest acquisition was incorrect.